Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Delays part of the FDA process...
View:
Post by wildbird1 on Oct 01, 2024 10:01am

Delays part of the FDA process...

Some debbie downer (some call them bashers) pretend that the delays caused by the FDA asking TLT for extra duration data is unusual...

In this link...Form 8-K for Immunitybio INC filed 05/11/2023

Item 8.01
It said ''The FDA requested that the company(ImmunityBio) provide updated duration of response data of the efficacy population identified by the FDA  in the company resubmission, as well as safety update.''

-Does the above sound familiar????

Note: Adstiladrin approval was also delayed by many FDA requests.

In short...
The FDA asking for extra duration of response data is part of the FDA BTD process.



.
Comment by tdon1229 on Oct 01, 2024 10:48am
More likely, however, it's associated with management's assumptions.  Did you ever read the Forward-Looking Statements section that is included in each NR? Here's a portion that each investor should read for understanding: Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward ...more  
Comment by Infinity on Oct 01, 2024 11:32am
Yes this Management lacks credibility.  You can try and justify all the delays perhaps place the blame on soneone else.  There is no other solution to a JV with a known pharma company to go ahead.
Comment by Longholder99 on Oct 01, 2024 12:18pm
Other than delays caused by a worldwide pandemic (2yr), or FDA policy revisions, (both not in mgmt control) or an effort ( I believe) to manage funding incrementally to minimize dilution and maintain ownership of patents.  What material delays are you referring to?   I say this with one eye on the fact that pre BTD may have already been submitted.   
Comment by Infinity on Oct 01, 2024 12:57pm
Long holder, are you comfortable with all the delays.  Do you have other reasons to be complacent with the the management with rewarding themselves and being opaqe with their communications?
Comment by Longholder99 on Oct 01, 2024 1:25pm
I am comfortable with the procedural delays when I consider that the test subjects stopped when the pandemic slammed the door shut. Causing us to be where we are now instead of where we will be in a year ot more.   I am fine with the financing happening the way it has having spoken to Mathew Perraton 2x.   Also due to delays from the pandemic causing extended periods of burn ...more  
Comment by Dumbeldorfwhite on Oct 01, 2024 6:33pm
This post has been removed in accordance with Community Policy
Comment by CancerSlayer on Oct 01, 2024 1:46pm
Agree...though incremental steps can be slow & painful, they often are externally influenced & internally calculated for the betterment of patients & shareholders, respectively.  I also agree that the pre-BTD has already likely been submitted.  Any kind of announcement re: a "pre-BTD" submission would be short on substance & long on shareholder consolation ...more  
Comment by Infinity on Oct 01, 2024 11:57am
Wild with due respect,  I think you are completely off target.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250